September 13, 2010
Otsuka Pharmaceutical Co., Ltd.
The Antiplatelet Agent Pletaal® (Nonproprietary Name: Cilostazol)
The Results of CSPS 2, a Large-Scale Clinical Trial of Cilostazol in Preventing Recurrent Strokes, Posted on the Online Version of The Lancet Neurology
Tokyo, Japan -- Otsuka Pharmaceutical Co., Ltd. today announced that the results of CSPS 2,* a large-scale clinical trial of cilostazol (Product Name: Pletaal) in preventing recurrent strokes, were posted on the online version of The Lancet Neurology, a British major medical journal in neurology, on September 11, 2010.
- * CSPS 2: Cilostazol Stroke Prevention Study 2
Information in this news release was current as of the original release date.